Arbutus Biopharma Corp (ABUS) Return on equity 2016–2025
Arbutus Biopharma Corp (ABUS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-43.7%FY2025 · since FY2016: -189.2% → -43.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -43.7% | +28.1 pp |
| FY2024 | -71.8% | -3.1 pp |
| FY2023 | -68.7% | -18.0 pp |
| FY2022 | -50.8% | -5.8 pp |
| FY2021 | -45.0% | +17.5 pp |
| FY2020 | -62.5% | +148.8 pp |
| FY2019 | -211.3% | -182.8 pp |
| FY2018 | -28.5% | +17.8 pp |
| FY2017 | -46.3% | +143.0 pp |
| FY2016 | -189.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice